Multiple Sclerosis Clinical Trials in New York

Showing 401-420 of 812 trials

RELAXaHEAD for Headache Patients (Phase I)

NCT03183791

The goal of this research is to assess the utility of smartphone-based progressive muscle relaxation (PMR) for the treatment of headaches. While there are many commercially available electronic diary and mind-body intervention apps for headache, there is little data showing their efficacy. RELAXaHEAD app incorporates the electronic PMR that was successfully used in an earlier epilepsy study and beta tested with headache specialist and migraine patient input. It also is an electric headache diary. This 2-arm randomized controlled study will evaluate the feasibility and acceptability of RELAX for use with headache patients. One arm will be the RELAX group (the RELAXaHEAD app) and the other arm will be a monitored usual care (MUC) group (this group receives standard of care and uses the electronic daily symptom reporting diary). The goals are to assess the feasibility and adherence of the RELAX intervention in persons with headache (Aim 1) and to gather exploratory data on the effects of the RELAX intervention on headache related outcome measures (Aim 2).

HeadacheMigraineMultiple Sclerosis

NYU Langone Health402 participantsStarted Nov 2017

New York, New York, United States

COMPLETEDNA< 1 mile

Emotion Regulation Therapy for Clinical Worry and Rumination

NCT04060940

The present project aims to broaden our understanding of neural mechanisms which may underlie change in symptoms occurring over the course of Emotion Regulation Therapy. Specifically, we aim to examine neural changes as a result of either an 8-session or 16-session version of the treatment.

Anxiety Disorders and SymptomsDepression, AnxietyGeneralized Anxiety Disorder+1 more

Douglas Mennin72 participantsStarted Nov 2015

New York, New York, United States

RELAXaHEAD for Headache Patients (Phase I)

Emotion Regulation Therapy for Clinical Worry and Rumination

Multiple Sclerosis Trials in Other Cities

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

A Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple Sclerosis

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS)

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Applying Speed of Processing Training to Individuals With Multiple Sclerosis

Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Other Conditions in New York